Keytruda: New Immunotherapy Drug for Melanoma Wins FDA Approval

The Food and Drug Administration has approved a new type of  immunotherapy drug that will provide a much-needed option for patients with advanced or inoperable melanoma who no longer respond to other drugs – including the immunotherapy agent ipilimumab (Yervoy).

F. Stephen Hodi, MD, director of the Center for Melanoma Oncology at Dana-Farber Cancer Institute

F. Stephen Hodi, MD, director of the Center for Melanoma Oncology at Dana-Farber Cancer Institute

The drug, pembrolizumab or MK-3745, will be marketed under the name  Keytruda. Based on impressive performance in clinical trials, the FDA had designated pembrolizumab a “breakthrough therapy” and placed it on a fast-tracked approval process.

“This drug is exciting because of its really striking response rate and good indications that these responses are durable” for a least a year, says Patrick Ott, MD, PhD, clinical director of the Center for Immuno-Oncology at Dana-Farber.  “And it is very well tolerated, with very manageable side effects,” he adds. The drug has been available, alone and in combination with other drugs, in clinical trials conducted at the center.

Both Keytruda and Yervoy unleash the search-and-destroy power of the body’s immune system against cancer cells. These drugs, as well as others in clinical trials, are arriving on the crest of a new wave of immunotherapy research, in which Dana-Farber scientists have played a prominent role.

Advanced melanoma is responsible for about 9,700 deaths a year in the United States, but the outlook for these patients is growing brighter with the remarkable outcomes brought about by immunotherapy.

The approval of Keytruda marks a first in the United States for a new class of immunotherapy drugs that block the PD-1 protein, which is commandeered by melanoma and other cancer cells to avoid detection and attack by the body’s immune system.

PD-1, along with a pair of partner molecules, PD-L1 (which was discovered by Dana-Farber’s Gordon Freeman, PhD and colleagues) and PD-L2, work together to protect normal cells from being mistakenly harmed by immune soldier cells that defend the body against foreign microbial invaders. Many cancers exploit the PD-1 pathway to hide from the immune response, and drugs like Keytruda inhibit PD-1, stripping the cancer cells of their shield against immune attack.

Keytruda is intended to be used following treatment with ipilimumab, which does not block PD-1 but instead targets another immune-suppressing protein, CTLA-4.

Stephen Hodi, MD, director of the Center for Melanoma Oncology and of the Center for Immuno-Oncology, called the new availability of pembrolizumab  “an important step forward that meets an unmet need” – that is, patients that don’t respond to ipilimumab or other treatments for advanced melanoma.

In an unusually large phase 1 trial of patients whose melanoma had spread throughout the body, Keytruda shrank tumors in about 30 percent of patients – including patients who had failed to respond to ipilimumab. After one year, 69 percent of patients were alive – a sharp improvement over the current outlook for such patients.

Ed. note: The FDA aapproved Bristol-Myers Squibb’s Opdivo, an immunotherapy drug for advanced skin cancer, on Dec. 22, 2014. Like Keytruda, Opdivo blocks the PD-1 protein, which is used by melanoma and other cancer cells to avoid detection and attack from the immune system. 

Comments Sort By Newest

4 thoughts on “Keytruda: New Immunotherapy Drug for Melanoma Wins FDA Approval

  1. I was diagnosed with Stage 4 Melanoma one year ago with advanced damage to my liver and spleen. Oncologists suggested my life expectancy was several months without treatment. I have been on a blind MK-3745 clinical trial and assume it was administered in combination with one month of Yervoy at the beginning. My results are spectacular! All tumors (with the exception of one holdout under my arm – which will be surgically removed next week) appear dissolved! I was very ill for several months and now anticipate a long and healthy life forward! Many thanks to all who helped develop MK-3745!

  2. Over the last 3 years I have been through all the standards plus for Stage 4 including Yervoy which was partially successful. I have only had 2 rounds of the Keytruda and my “golfball” on the side of my neck is all but gone. Hopeful it is doing the same for the internal tumors. This week is round three. Best thing is having none of the “wow am I sick” side effects. Just a little tired. Has anyone heard that Yervoy and Keytruda could be best used together? Best luck to all with the amazing new Keytruda!

  3. Hallo, i had multiple metastases in lung, bone, lymphatic nodes in mediastinum, pelvine and in muscles. After 4 Treatments with pemprolizumab, there is NO activity Seen in PET CT Scan! Realy Amazing!!! Nobody knows how Long this effect will last but i’m happy with this best possible result!

  4. Hello. I am on this trial and it has worked like magic for me. All my tumors are shrinking and some are gone. Amazing drug:)

  5. Hello. I am on this trial and it has worked like magic for me. All my tumors are shrinking and some are gone. Amazing drug:)

  6. Hallo, i had multiple metastases in lung, bone, lymphatic nodes in mediastinum, pelvine and in muscles. After 4 Treatments with pemprolizumab, there is NO activity Seen in PET CT Scan! Realy Amazing!!! Nobody knows how Long this effect will last but i’m happy with this best possible result!

  7. Over the last 3 years I have been through all the standards plus for Stage 4 including Yervoy which was partially successful. I have only had 2 rounds of the Keytruda and my “golfball” on the side of my neck is all but gone. Hopeful it is doing the same for the internal tumors. This week is round three. Best thing is having none of the “wow am I sick” side effects. Just a little tired. Has anyone heard that Yervoy and Keytruda could be best used together? Best luck to all with the amazing new Keytruda!

  8. I was diagnosed with Stage 4 Melanoma one year ago with advanced damage to my liver and spleen. Oncologists suggested my life expectancy was several months without treatment. I have been on a blind MK-3745 clinical trial and assume it was administered in combination with one month of Yervoy at the beginning. My results are spectacular! All tumors (with the exception of one holdout under my arm – which will be surgically removed next week) appear dissolved! I was very ill for several months and now anticipate a long and healthy life forward! Many thanks to all who helped develop MK-3745!

Comments are closed.

Make An Appointment

For adults: 877-960-1562

Quick access: Appointments as soon as the next day for new adult patients

For children: 888-733-4662

All content in these blogs is provided by independent writers and does not represent the opinions or advice of Dana-Farber Cancer Institute or its partners.

Latest Tweets

Dana-Farber @danafarber
What is the Relationship Between Tea and #Cancer Prevention? https://t.co/mnYP2qfjtW https://t.co/N5LVaBSRZ2
Dana-Farber @danafarber
Missed Dana-Farber at #ASH17? Subscribe to our bi-annual e-newsletter, Advances in Hematologic Malignancies, to lea… https://t.co/kknkzq1qmL
Dana-Farber @danafarber
Congratulations to Dr. Edward Benz, president and chief executive officer emeritus of Dana-Farber Cancer Institute,… https://t.co/YH71ia6nn2

Republish our posts on your blog

Interested in sharing one of our stories on your blog? Feel free to republish this content! We just ask that you credit Dana-Farber, link to the original article, and refrain from making edits that change the original context. Questions? Email the editors at insight_blog@dfci.harvard.edu.